Celldex SVP granted 90,000 stock options

Celldex Therapeutics reported that SVP & Chief Commercial Officer Teri L. Lawver received an incentive stock option grant for 90,000 shares of common stock.

Rhea-AI Filing Summary

Celldex Therapeutics reported that SVP & Chief Commercial Officer Teri L. Lawver received an incentive stock option grant for 90,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.

According to the grant terms, 25% of the option vests on June 25, 2027, with the remaining portion vesting in equal quarterly installments over the following 12 quarters. Following this award, Lawver holds options covering 90,000 shares, reflecting a compensation-related equity incentive rather than an open-market transaction.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Lawver Teri L

Role SVP & Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	90,000	$0.00	$0.00

Holdings After Transaction: Incentive Stock Option (right to buy) — 90,000 contracts (Direct)

Footnotes (2)

1. F1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
2. F2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Key Figures

Option grant size: 90,000 options Exercise price: $34.09 per share Underlying shares: 90,000 shares +3 more

6 metrics

Option grant size 90,000 options Incentive Stock Option grant to SVP & CCO

Exercise price $34.09 per share Conversion price for the option grant

Underlying shares 90,000 shares Common stock underlying the incentive stock option

Expiration date June 25, 2036 Option term end date

Initial vesting date June 25, 2027 25% of options vest on this date

Post-transaction options held 90,000 options Total options held following this grant

Key Terms

Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vesting, underlying security

4 terms

Incentive Stock Option financial

"Incentive Stock Option (right to buy)"

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

2021 Omnibus Equity Incentive Plan financial

"option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan"

vesting financial

"25% vest on June 25, 2027 and the remainder vest quarterly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

underlying security financial

"underlying_security_title: Common Stock, underlying_security_shares: 90000.0000"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Celldex (CLDX) disclose in this Form 4 for Teri L. Lawver?

Celldex disclosed that SVP & Chief Commercial Officer Teri L. Lawver received an incentive stock option grant for 90,000 shares, providing her the right to buy common stock at a fixed exercise price as part of equity compensation.

How many Celldex (CLDX) shares are covered by Teri Lawver’s new option grant?

The new incentive stock option covers 90,000 shares of Celldex common stock. This entire amount was granted in a single award and represents her reported option holdings following this transaction in the Form 4 filing.

What is the exercise price of Teri Lawver’s Celldex (CLDX) stock options?

The incentive stock option granted to Teri Lawver has an exercise price of $34.09 per share. This is the price she must pay to purchase each share of Celldex common stock when the options are vested and exercised.

When do Teri Lawver’s Celldex (CLDX) stock options vest?

Twenty-five percent of the option grant vests on June 25, 2027. The remaining 75% vests in equal quarterly installments over the subsequent 12 quarters, creating a multi-year vesting schedule tied to continued service.

When do Teri Lawver’s Celldex (CLDX) incentive stock options expire?

The incentive stock options granted to Teri Lawver expire on June 25, 2036. After that expiration date, any unexercised portion of the 90,000-share grant will no longer be exercisable under the plan’s terms.

Is Teri Lawver buying or selling Celldex (CLDX) shares in this Form 4?

This Form 4 does not show open-market buying or selling. It reports a grant of incentive stock options to Teri Lawver as compensation, giving her the right to acquire shares in the future at a fixed exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lawver Teri L

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		90,000		06/25/2027(2)	06/25/2036	Common Stock	90,000	$0	90,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Sam Martin, attorney-in-fact for Teri Lawver	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)